To pursue the BioFusion objectives, we have defined a multidisciplinary approach that involves six interconnected Work Packages and an extra Governance Work Package. In WP1, a calcium phosphate (CaP)-based biomaterials with osteoinductive properties, load-bearing capacity will be developed. The CaP composition and topography will be tuned to enhance mechanical properties, and CaP-based inks for additive manufacturing  will be formulated. In WP2, nanoparticles incorporating bioinorganic therapeutic agents that control inflammation and promote bone regeneration will be developed by. The nanoparticle will be integrated into the CaP-based material ink for 3D printing. WP3 will be focused on the structural modelling and design of the interbody cage. The cage will be optimized to promote spinal fusion through mechanical stimulation while ensuring immediate and long-term structural integrity. WP4 will be focused on the manufacturing process of the device through extrusion-based printing with the load bearing and anti inflammatory biomaterial ink. In WP5,the osteogenic and anti-inflammatory potential, and mechanical properties of the implants will be tested within in vitro and ex vivo platforms. Finally,  the preclinical proof of concept for the engineered BioFusion cage for spinal fusion will be assessed in WP6 through an in-vivo sheep model. WP7 will take care of project management, dissemination and communication between partners.